FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208917623> ?p ?o ?g. }

• W3208917623 abstract "Background: Although acute myeloid leukaemia (AML) with RUNX1-RUNX1T1 and CBFB-MYH11 is categorized into a favorable cytogenetic risk group, several prognostic factors are suggested. However, those clinical significance remains controversial. We aimed to evaluate the prognostic relevance of gene mutations and minimal residual disease (MRD) in AML with RUNX1-RUNX1T1 and CBFB-MYH11.  Methods: In this phase 4 trial, we enrolled AML with RUNX1-RUNX1T1 or CBFB-MYH11 patients aged 16 to 64 years old who achieved complete remission. Patients received three courses of high-dose cytarabine therapy, but no further treatment until haematological relapse. We analyzed mutations in exons 8, 10-11, and 17 of the KIT gene, and 55 genes that are frequently identified in myeloid malignancies, and also evaluated MRD. The primary endpoint was relapse-free survival (RFS) according to KIT mutation. This study is registered with UMIN Clinical Trials Registry, number UMI03434.  Findings: Between May 25, 2010, and September 10, 2014, 203 patients were enrolled, and 199 patients were eligible. Median follow-up was 52·2 months (IQR 39·2-62·2). The primary endpoint RFS in KIT-mutated patients was inferior to that in unmutated patients (hazard ratio [HR] 1·92; 95% CI 1·23-3·00; p=0·003). Subgroup analysis showed a prognostic impact of KIT mutation in patients with RUNX1-RUNX1T1 (HR 3·27; 95% CI 1·90-5·64; p<0·001), but not in those with CBFB-MYH11, and only exon 17 mutation had such a notable impact. MRD was evaluated in 112 patients, and its presence was associated with a lower RFS in patients with CBFB-MYH11 (HR 4·55; 95% CI 1·20-17·2; p=0·03), but not in those with RUNX1-RUNX1T1.  Interpretation: KIT exon 17 mutation was an unfavorable prognostic factor for RFS in AML patients with RUNX1-RUNX1T1. In contrast, the positivity of MRD was an unfavorable prognostic factor for RFS in AML patients with CBFB-MYH11.  Trial Registration Number: This study is registered with UMIN Clinical Trials Registry, number UMI03434. Funding: Japan Agency for Medical Research and Development (AMED).Conflict of Interest: HKi received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., and Celgene Corporation, consulting fees from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., and Daiichi Sankyo Co., Ltd., and honoraria from Bristol-Myers Squibb. NDob received research funding from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Celgene Co., and Sysmex Co. NA received research funding from Chugai Pharmaceutical Co., Ltd., and Toyama Chemical Co., Ltd., and consulting fee from SRL Inc. No other potential conflict of interest relevant to this article was reported. Ethical Approval: The protocol was approved by the Ethics Committees of all participating institutions." @default.
• W3208917623 created "2021-11-08" @default.
• W3208917623 creator A5001496361 @default.
• W3208917623 creator A5002642944 @default.
• W3208917623 creator A5003175331 @default.
• W3208917623 creator A5010994282 @default.
• W3208917623 creator A5013146671 @default.
• W3208917623 creator A5015344411 @default.
• W3208917623 creator A5021856829 @default.
• W3208917623 creator A5030138511 @default.
• W3208917623 creator A5030597247 @default.
• W3208917623 creator A5033486602 @default.
• W3208917623 creator A5036422444 @default.
• W3208917623 creator A5042351719 @default.
• W3208917623 creator A5043062893 @default.
• W3208917623 creator A5045468227 @default.
• W3208917623 creator A5046884055 @default.
• W3208917623 creator A5046989635 @default.
• W3208917623 creator A5048061147 @default.
• W3208917623 creator A5050447571 @default.
• W3208917623 creator A5061599783 @default.
• W3208917623 creator A5063503238 @default.
• W3208917623 creator A5066198255 @default.
• W3208917623 creator A5067223666 @default.
• W3208917623 creator A5070702322 @default.
• W3208917623 creator A5071962895 @default.
• W3208917623 creator A5074979030 @default.
• W3208917623 creator A5084655190 @default.
• W3208917623 creator A5090508237 @default.
• W3208917623 creator A5090903462 @default.
• W3208917623 date "2019-01-01" @default.
• W3208917623 modified "2023-10-15" @default.
• W3208917623 title "Prospective Evaluation of Prognostic Relevance of Gene Mutations and Minimal Residual Disease in Acute Myeloid Leukaemia with RUNX1-RUNX1T1 or CBFB-MYH11" @default.
• W3208917623 doi "https://doi.org/10.2139/ssrn.3343673" @default.
• W3208917623 hasPublicationYear "2019" @default.
• W3208917623 type Work @default.
• W3208917623 sameAs 3208917623 @default.
• W3208917623 citedByCount "0" @default.
• W3208917623 crossrefType "journal-article" @default.
• W3208917623 hasAuthorship W3208917623A5001496361 @default.
• W3208917623 hasAuthorship W3208917623A5002642944 @default.
• W3208917623 hasAuthorship W3208917623A5003175331 @default.
• W3208917623 hasAuthorship W3208917623A5010994282 @default.
• W3208917623 hasAuthorship W3208917623A5013146671 @default.
• W3208917623 hasAuthorship W3208917623A5015344411 @default.
• W3208917623 hasAuthorship W3208917623A5021856829 @default.
• W3208917623 hasAuthorship W3208917623A5030138511 @default.
• W3208917623 hasAuthorship W3208917623A5030597247 @default.
• W3208917623 hasAuthorship W3208917623A5033486602 @default.
• W3208917623 hasAuthorship W3208917623A5036422444 @default.
• W3208917623 hasAuthorship W3208917623A5042351719 @default.
• W3208917623 hasAuthorship W3208917623A5043062893 @default.
• W3208917623 hasAuthorship W3208917623A5045468227 @default.
• W3208917623 hasAuthorship W3208917623A5046884055 @default.
• W3208917623 hasAuthorship W3208917623A5046989635 @default.
• W3208917623 hasAuthorship W3208917623A5048061147 @default.
• W3208917623 hasAuthorship W3208917623A5050447571 @default.
• W3208917623 hasAuthorship W3208917623A5061599783 @default.
• W3208917623 hasAuthorship W3208917623A5063503238 @default.
• W3208917623 hasAuthorship W3208917623A5066198255 @default.
• W3208917623 hasAuthorship W3208917623A5067223666 @default.
• W3208917623 hasAuthorship W3208917623A5070702322 @default.
• W3208917623 hasAuthorship W3208917623A5071962895 @default.
• W3208917623 hasAuthorship W3208917623A5074979030 @default.
• W3208917623 hasAuthorship W3208917623A5084655190 @default.
• W3208917623 hasAuthorship W3208917623A5090508237 @default.
• W3208917623 hasAuthorship W3208917623A5090903462 @default.
• W3208917623 hasConcept C104317684 @default.
• W3208917623 hasConcept C126322002 @default.
• W3208917623 hasConcept C143998085 @default.
• W3208917623 hasConcept C207103383 @default.
• W3208917623 hasConcept C2778461978 @default.
• W3208917623 hasConcept C2779823535 @default.
• W3208917623 hasConcept C2994225774 @default.
• W3208917623 hasConcept C44249647 @default.
• W3208917623 hasConcept C501734568 @default.
• W3208917623 hasConcept C54355233 @default.
• W3208917623 hasConcept C63363279 @default.
• W3208917623 hasConcept C71924100 @default.
• W3208917623 hasConcept C86803240 @default.
• W3208917623 hasConceptScore W3208917623C104317684 @default.
• W3208917623 hasConceptScore W3208917623C126322002 @default.
• W3208917623 hasConceptScore W3208917623C143998085 @default.
• W3208917623 hasConceptScore W3208917623C207103383 @default.
• W3208917623 hasConceptScore W3208917623C2778461978 @default.
• W3208917623 hasConceptScore W3208917623C2779823535 @default.
• W3208917623 hasConceptScore W3208917623C2994225774 @default.
• W3208917623 hasConceptScore W3208917623C44249647 @default.
• W3208917623 hasConceptScore W3208917623C501734568 @default.
• W3208917623 hasConceptScore W3208917623C54355233 @default.
• W3208917623 hasConceptScore W3208917623C63363279 @default.
• W3208917623 hasConceptScore W3208917623C71924100 @default.
• W3208917623 hasConceptScore W3208917623C86803240 @default.
• W3208917623 hasLocation W32089176231 @default.
• W3208917623 hasOpenAccess W3208917623 @default.
• W3208917623 hasPrimaryLocation W32089176231 @default.
• W3208917623 hasRelatedWork W2011547634 @default.
• W3208917623 hasRelatedWork W2113317673 @default.
• W3208917623 hasRelatedWork W2793719541 @default.
• W3208917623 hasRelatedWork W2913046520 @default.

• next